Affirming support for most-favored-Nation drug pricing for United States patients.
- Bill Number
- H.Res. 928
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-12-04: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2025-12-06T14:19:17Z
AI-Generated Summary
Purpose
This House Resolution (H. Res. 928) expresses the House of Representatives' support for implementing "most-favored-nation" (MFN) drug pricing policies. MFN pricing aims to ensure that prescription drug prices in the United States match the lowest prices paid by other developed nations, addressing the high cost of medications for American patients.
Key Provisions
- Support for Equal Pricing: Affirms that U.S. patients should not pay more for the same prescription drugs than patients in other countries.
- Commitment to Cost Reduction: Recognizes the need to lower drug costs through:
- Policies aligning U.S. drug prices with those in other developed nations.
- Expanding Medicare's ability to negotiate drug prices directly with manufacturers.
- Promoting competition in the drug market to drive down prices.
- Access to Affordable Drugs: Supports ensuring U.S. citizens have access to high-quality, affordable prescription medications.
The resolution is based on "Whereas" clauses citing data on high U.S. drug spending (e.g., 2.78 times higher than in comparable countries), per capita costs exceeding $1,400 annually, and patient hardships like skipping doses due to expense. It references bipartisan support, a 2025 Executive Order by President Trump on MFN pricing, letters to pharmaceutical companies, and related congressional legislation.
Significant Changes to Existing Law
This is a non-binding resolution, so it introduces no direct changes to existing laws or regulations. It serves as a declarative statement of congressional intent, potentially influencing future legislation or executive actions without legal force.
Potential Impacts
- On Citizens: Could encourage policies reducing out-of-pocket drug costs, potentially benefiting the 21% of adults who skip prescriptions due to price and improving access to medications for millions.
- On Government Agencies: Supports actions by the Department of Health and Human Services (HHS) and Medicare in negotiating prices, aligning with executive initiatives to lower federal spending on drugs.
- On International Relations: May pressure pharmaceutical companies to standardize global pricing, affecting trade negotiations with other developed nations (e.g., via the Organization for Economic Cooperation and Development) and highlighting U.S. concerns over unequal pricing.
- Broader Economy: If implemented through related policies, it could reduce overall U.S. healthcare spending, which is disproportionately high on new drugs.
Main Stakeholders Affected
- U.S. Patients and Citizens: Primary beneficiaries through potential lower drug prices and reduced financial burdens.
- Pharmaceutical Manufacturers: Face pressure to lower U.S. prices to match international levels, impacting profits and pricing strategies.
- Government Entities: Includes Congress, the executive branch (e.g., HHS, Medicare), and bipartisan lawmakers supporting drug pricing reforms.
- Healthcare Providers and Insurers: Indirectly affected by changes in drug affordability and market competition.
Notable Legal, Constitutional, or Political Implications
- Legal: As a simple resolution, it has no binding effect but reinforces the constitutionality of congressional oversight on commerce and healthcare policy under Article I. It aligns with existing laws like the Medicare Prescription Drug, Improvement, and Modernization Act by endorsing expanded negotiation powers.
- Constitutional: Supports the federal government's role in regulating interstate commerce (drugs) without infringing on states' rights, though implementation could raise questions about executive authority in trade and pricing.
- Political: Demonstrates bipartisan consensus on drug pricing (introduced by Reps. Dingell and Crane), building on prior administrations' efforts. It politically bolsters executive actions like the 2025 Trump order, potentially influencing midterm or future elections by addressing a popular issue (high drug costs) while challenging the pharmaceutical industry's influence in lobbying.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2025-12-04: Referred to the House Committee on Energy and Commerce.
- 2025-12-04: Submitted in House
- 2025-12-04: Submitted in House
Bill Versions
- Affirming support for most-favored-Nation drug pricing for United States patients. — issued 2025-12-04 — PDF (3 pages)